Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2009 1
2012 3
2013 3
2014 2
2015 3
2016 2
2017 3
2019 3
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C, Davies AM, Mahgoub T, Ballot J, Toomey S, O'Connor DP, Gallagher WM, Holmes FA, Espina V, Liotta L, Hennessy BT, O'Byrne KJ, Hasmann M, Bossenmaier B, O'Donovan N, Crown J. Collins DM, et al. Among authors: bossenmaier b. Clin Cancer Res. 2021 Feb 1;27(3):807-818. doi: 10.1158/1078-0432.CCR-20-2007. Epub 2020 Oct 29. Clin Cancer Res. 2021. PMID: 33122343 Free PMC article. Clinical Trial.
Acquired Resistance to Antibody-Drug Conjugates.
Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Collins DM, et al. Among authors: bossenmaier b. Cancers (Basel). 2019 Mar 20;11(3):394. doi: 10.3390/cancers11030394. Cancers (Basel). 2019. PMID: 30897808 Free PMC article. Review.
The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
Peper-Gabriel JK, Pavlidou M, Pattarini L, Morales-Kastresana A, Jaquin TJ, Gallou C, Hansbauer EM, Richter M, Lelievre H, Scholer-Dahirel A, Bossenmaier B, Sancerne C, Riviere M, Grandclaudon M, Zettl M, Bel Aiba RS, Rothe C, Blanc V, Olwill SA. Peper-Gabriel JK, et al. Among authors: bossenmaier b. Clin Cancer Res. 2022 Aug 2;28(15):3387-3399. doi: 10.1158/1078-0432.CCR-21-2762. Clin Cancer Res. 2022. PMID: 35121624 Free PMC article.
DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.
Sustmann C, Dickopf S, Regula JT, Kettenberger H, Mølhøj M, Gassner C, Weininger D, Fenn S, Manigold T, Kling L, Künkele KP, Schwaiger M, Bossenmaier B, Griese JJ, Hopfner KP, Graff-Meyer A, Stahlberg H, Ringler P, Lauer ME, Brinkmann U, Schaefer W, Klein C. Sustmann C, et al. Among authors: bossenmaier b. MAbs. 2019 Nov-Dec;11(8):1402-1414. doi: 10.1080/19420862.2019.1661736. Epub 2019 Sep 17. MAbs. 2019. PMID: 31526159 Free PMC article.
Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial.
Ducret A, James I, Wilson S, Feilke M, Tebbe A, Dybowski N, Elschenbroich S, Klammer M, Blackler A, Liao WL, Tian Y, Friess T, Bossenmaier B, Dietmann G, Schaab C, Hembrough T, Ceppi M. Ducret A, et al. Among authors: bossenmaier b. PLoS One. 2019 Mar 21;14(3):e0213892. doi: 10.1371/journal.pone.0213892. eCollection 2019. PLoS One. 2019. PMID: 30897176 Free PMC article. Clinical Trial.
Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.
Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G. Bauss F, et al. Among authors: bossenmaier b. Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14. Mol Oncol. 2016. PMID: 27507537 Free PMC article.
Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy.
Kollmorgen G, Niederfellner G, Lifke A, Spohn GJ, Rieder N, Harring SV, Bauss F, Burtscher H, Lammers R, Bossenmaier B. Kollmorgen G, et al. Among authors: bossenmaier b. Mol Oncol. 2013 Dec;7(6):1142-51. doi: 10.1016/j.molonc.2013.08.009. Epub 2013 Sep 3. Mol Oncol. 2013. PMID: 24055141 Free PMC article.
21 results